Global biopharmaceutical company: Protecting a public commitment to the market

1 min read

Execution Tracking

A biopharmaceutical company’s chief executive publicly promised investors it would file a major regulatory application by the end of the first quarter, but the internal plan had it more than 44 days later. We helped the company re-sequence its work and re-aim its resources to protect that promise, filing well within the quarter and securing first-to-market status.

Outcome 1: The application was filed 44 days ahead of the original internal plan, within the first quarter
Outcome 2: First-to-market status secured
Outcome 3: Positive analyst ratings restored and significant commercial value protected

The challenge

The chief executive of a global biopharmaceutical company made a public promise to Wall Street analysts: the company would file its Biologics License Application, the formal request to sell a new biological medicine, by the end of the first quarter. The internal plan had the filing scheduled for late April at the earliest. The gap between the public promise and the reality was more than 44 days, and resources were not aligned to close it.

Filing in late April would break the first-quarter promise, trigger a negative reaction from analysts, and hand first-to-market status to a competitor. Months of careful positioning and significant commercial value would be lost.

The approach

Working with the leadership team, we treated the chief executive’s public commitment as non-negotiable rather than a target. We re-sequenced the order of the work, re-aimed resources, and designed new ways for teams to coordinate specifically to protect first-quarter delivery. Risks were surfaced early and managed actively, rather than escalated once they had already become problems.

The impact

The application was filed 44 days ahead of the original internal plan, comfortably within the first quarter, and the chief executive’s public promise was kept in full. The company secured first-to-market status, restored positive analyst ratings, and protected significant commercial value that would otherwise have been lost to a competitor.